High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

Shares of Swedish Orphan Biovitrum AB (STO:SOBI) fell 3% as the company's fourth-quarter earnings report revealed mixed results. While overall Q4 revenue met consensus expectations, sales of its key ...

Public is encouraged to document orca sightings, which could help find the 2-year-old female calf last seen in fall, 2024 ...

Adolore BioTherapeutics (”Adolore” or the “Company”), is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS to treat the ...

In arid West Texas, water seeps and bubbles from old wells, sometimes carrying oil, brackish water or other pollutants to the surface. But the real danger lies underground — where oil, salt, and toxic ...

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

Despite some market exclusivity concerns, GERN still has many years of sales ahead, unencumbered by generic competition.

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

The alabaster chandelier by Orphan Work maintains the elegant vaulted ceiling, and dappled light from tinted stained glass ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

From the first note of 'Tomorrow' to the final curtain call, Annie at Clowes Memorial Hall is a dazzling and joyous ...

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive ...